MarginsXMarginsX
Home › Markets › Industrials › NAUT

Nautilus Biotechnology Inc. (NAUT)

NAUT trades on Nasdaq in Industrials, Biotechnology: Laboratory Analytical Instruments. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$2.10
-9.48% on the day
Market cap
$267.5M
Micro cap
Revenue
Not reported in SEC XBRL data
Net income
Not reported in SEC XBRL data

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.

Profile

FieldValue
TickerNAUT on Nasdaq
SectorIndustrials
IndustryBiotechnology: Laboratory Analytical Instruments
CountryUnited States
IPO year2020
SEC CIK0001808805
SEC industry codeLaboratory Analytical Instruments
Incorporated inDELAWARE

Financials

Not reported in SEC XBRL data.

Warning signs

Cash runway
2.4 months
$10.5M cash at September 30, 2026
Share count, 1 year
+0.8%
2025-10-23 to 2026-10-22 · +1.9% over 3 years
Going-concern doubt
No
10-Q filed October 27, 2026
Insider net buying, 12 months
-$11.7M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-10-27
Cash and burn$10.5M cash; operating cash flow -$13.1M a quarter.Report 2026-09-30
Shares outstanding127,372,425 (2026-10-22); 126,305,122 a year earlier; 124,945,774 three years earlier.Cover page 2026-10-22
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the marketLatest 2026-09-18
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorPricewaterhouseCoopers LLP, San Jose, California, United StatesPCAOB Form AP 2026-03-09
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $71K, sold $11.8M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$234K-$15.6M-$13.3M$10.5MNo debt tagsNeeds four quarters10-Q 2026-10-27
Q2 2026
2026-06-30
$190K-$14.5M-$13.7M$13.2MNo debt tagsNeeds four quarters10-Q 2026-07-28
Q1 2026
2026-03-31
Not filed-$14.7M-$13.1M$14.6MNo debt tagsNeeds four quarters10-Q 2026-04-28
Q4 2025
2025-12-31
Not filed-$13.8M-$12.4M$12.4MNo debt tagsNeeds four quarters10-K 2026-02-26
Q3 2025
2025-09-30
$0-$13.6M-$11.0M$23.9MNo debt tagsNeeds four quarters10-Q 2026-10-27
Q2 2025
2025-06-30
$0-$15.0M-$13.3M$34.5MNo debt tagsNeeds four quarters10-Q 2026-07-28
Q1 2025
2025-03-31
Not filed-$16.6M-$13.9M$33.2MNo debt tagsNeeds four quarters10-Q 2026-04-28
Q4 2024
2024-12-31
Not filed-$17.6M-$14.3M$27.6MNo debt tagsNeeds four quarters10-K 2026-02-26

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-09-18
Latest annual report10-K2026-02-26
Latest quarterly / interim10-Q2026-10-27
Latest current report8-K2026-10-27
Latest proxyDEFA14A2026-04-28

Source: SEC EDGAR submissions feed, 328 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+4.0%
1 month+13.2%
3 months+160.7%
Year to date+19.0%
1 year+22.8%
From 52-week high-41.3%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Laboratory Analytical Instruments

TickerCompanyPriceDayMarket cap
LABStandard BioTools Inc.$0.6210-12.21%$245.2M
QTRXQuanterix Corporation$2.84-3.07%$134.8M
PACBPacific Biosciences of California Inc.$1.84-6.12%$575.8M
CTKBCytek Biosciences Inc.$5.63-3.60%$736.3M
SEERSeer Inc.$1.48-5.73%$82.6M
HBIOHarvard Bioscience Inc.$8.91-5.96%$40.7M
RPIDRapid Micro Biosystems Inc.$0.7400+13.67%$37.1M
PRPOPrecipio Inc.$19.96-9.81%$35.8M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier